Secondary analysis of a trial of intranasal ketamine for depression in 15 patients with advanced cancer receiving palliative care: after 3 doses, anxiety, death and dying distress, symptom and quality-of-life scores improved beyond minimal clinically important differences.
Secondary analysisn = 15
Aguiar et al. Intranasal Ketamine for Existential Distress in Advanced Cancer